Paris, Île-de-France, France, September 2025 — Jaime Arango has been appointed as the Chief Financial Officer (CFO) at Adcytherix, a biotech company dedicated to advancing antibody drug conjugates for the treatment of high unmet need diseases such as cancer. In his new role, Jaime will oversee the company’s global financial strategy, corporate governance, and funding initiatives to support its ambitious growth and innovation agenda.
Jaime joins Adcytherix from TreeFrog Therapeutics, where he served as Group Chief Financial Officer for two years. Based between Bordeaux and Paris, he played a central role in financial consolidation, strategic planning, fundraising, and operational excellence, helping the company navigate a dynamic biotech investment landscape.
Before TreeFrog, he was Group CFO at MedinCell from 2017 to 2023, where he successfully led an IPO and follow-on listing on Euronext Paris, implemented scenario-based forecasting, optimized non-dilutive financing, and strengthened internal controls and risk management systems.
Previously, Jaime spent two years as VP Finance at Revlon Professional Brands in Miami, where he managed regional finance operations, working capital, and financial consolidation. Earlier, he spent over nine years at Merck (MSD) in progressive leadership roles, including Director – Global Finance Transformation, Head of Finance – Balkans Region, Head of FP&A – Internal Control MSD France, and Strategic Planning Manager. These roles gave him a global perspective across Europe, the Balkans, and France, with expertise in governance, scenario planning, and internal controls.
Jaime began his career in finance as a Senior Treasury/Financial Analyst at Biogen Idec in Paris. His strong technical foundation and leadership experience across multinational corporations and biotech innovators make him well-positioned to lead Adcytherix’s financial strategy.
An MBA graduate of HEC Paris with an exchange at The Wharton School, Jaime also holds a degree in Industrial Engineering from Universidad de Los Andes. His educational and professional journey reflects a deep expertise in finance, operations, and international corporate governance.
About Adcytherix
Adcytherix BV is a biotechnology company focused on the development of antibody drug conjugates (ADCs) for high unmet medical needs, particularly in oncology. With cutting-edge science and a mission to transform cancer care, Adcytherix is committed to advancing innovative therapies that combine precision targeting with therapeutic efficacy, offering new hope to patients worldwide.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
